Copyright
©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1258-1167
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1258
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1258
Table 2 Types of proprotein convertase subtilisin/kexin type-9 inhibitor used by the study population
| Males | Females | Total | |
| Type of PCSK9 inhibitor | |||
| Evolocumab | 5 | 17 | 22 |
| Alirocumab | 3 | 4 | 7 |
| Age in year at PCSK9 inhibitor initiation, mean ± SD | 67.7 ± 7.6 | 63.6 ± 9.6 | 64.8 ± 9.1 |
| Concomitant statin therapy during PCSK-9 therapy | 1 | 5 | 6 |
- Citation: Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1167
- URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1258.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1258